H

Heart Clinic of Hammond | Hammond, LA

Research site

(Unclaimed)

Location

16033 Doctors Boulevard, Hammond, Louisiana, United States of America

Site insights

Top conditions

Top treatments

BI 456906

Empagliflozin

Vericiguat

BI 690517

Ziltivekimab

Semaglutide

Iron

Survodutide

Finerenone

Dronedarone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 16 total trials

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

Locations recently updated

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling

Obesity

Drug: Placebo

Drug: survodutide

Locations recently updated

A Study to Test Whether BI 690517 in Combination With Empagliflozin Helps People With Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling

Heart Failure

Drug: BI 690517

Drug: Empagliflozin

Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation (CHANGE-AFIB)

While there are several completed clinical trials that address treatment strategy in patients with symptomatic and recurrent AF, there are no randomi...

Active, not recruiting

Atrial Fibrillation

Drug: Dronedarone

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg